Year 2021 / Volume 113 / Number 2
Letter
Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn’s disease

154-155

DOI: 10.17235/reed.2020.7232/2020

Angelo Viscido, Giovanni Latella,

Abstract
We read with great interest the article “Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn’s disease: an observational study” by Ribaldone et al., which was recently published in your journal. The authors report the first real-life study of the adalimumab biosimilar ABP 501 in Crohn’s disease (CD). The study investigated the short-term effectiveness and safety of ABP 501 in 87 patients with CD, 25 patients naïve to adalimumab and 62 switched from the adalimumab originator. A meaningful proportion of CD patients treated with ABP 501 showed clinical benefit with a satisfactory safety profile until the end of follow-up.
Share Button
New comment
Comments
No comments for this article
References
1. Ribaldone DG, Caviglia GP, Pellicano R, et al. Effectiveness and safety of adalimumab biosimilar ABP 501 in Crohn's disease: an observational study. Rev Esp Enferm Dig 2020; 112: 195-200. DOI: 10.17235/reed.2020.6693/2019.
2. Fiorino G, Caprioli F, Daperno M, et al. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis 2019; 51: 632-639. DOI: 10.1016/j.dld.2019.02.004.
3. Liu J, Eris T, Li C, et al. Assessing analytical similarity of proposed amgen biosimilar ABP 501 to adalimumab. BioDrugs 2016; 30: 321-38. DOI: 10.1007/s40259-016-0184-3.
4. Velayudhan J, Chen YF, Rohrbach A, et al. Demonstration of functional similarity of proposed biosimilar ABP 501 to adalimumab. BioDrugs 2016; 30: 339-51. DOI: 10.1007/s40259-016-0185-2.
5. Kaur P, Chow V, Zhang N, et al. A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab. Ann Rheum Dis 2017; 76: 526-533. DOI: 10.1136/annrheumdis-2015-208914. Epub 2016 Jul 27.
Related articles

Letter

Duodenal stenosis surgical treatment in Crohn’s disease

DOI: 10.17235/reed.2023.9521/2023

Digestive Diseases Image

Peristomal cutaneous Crohn's disease by contiguity

DOI: 10.17235/reed.2022.8909/2022

Letter

Anal neoplasia and perianal Crohn’s disease: myth or reality?

DOI: 10.17235/reed.2021.8317/2021

Letter

Crohn’s disease in patients treated with etanercept

DOI: 10.17235/reed.2019.6554/2019

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Letter to the Editor

Adnexal localization of Crohn’s disease and recurrent massive ovary cysts

DOI: 10.17235/reed.2016.4301/2016

Case Report

Metastatic Crohn’s disease in pediatrics

DOI: 10.17235/reed.2016.3948/2015

Letter to the Editor

Crohn’s disease and Sweet’s syndrome: A debut together

DOI: 10.17235/reed.2015.3842/2015

Case Report

Ovarian involvement in Crohn´s disease: A rare complication

DOI: 10.17235/reed.2015.3764/2015

Citation tools
Viscido A, Latella G. Effectiveness and safety of switching to adalimumab biosimilar ABP 501 in Crohn’s disease. 7232/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 376 visits.
This article has been downloaded 171 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 06/05/2020

Accepted: 12/05/2020

Online First: 19/11/2020

Published: 08/02/2021

Article Online First time: 197 days

Article editing time: 278 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology